Zydus Lifesciences’ Verapamil Approval Analyzed
Zydus Lifesciences has just gotten the green light from the US Food and Drug Administration (USFDA) to sell Verapamil Hydrochloride Extended-Release Tablets. These tablets come in three strengths – 120 mg, 180 mg, and 240 mg. They’re a copy of a medicine already on the market called Calan SR Extended-Release, and they’re used to help lower high blood pressure and reduce the risk of serious heart problems like strokes and heart attacks.
Key Points
- USFDA approved Verapamil tablets for high blood pressure management.
- Generic version of Calan SR, boosting heart health significantly.
- $24.5 million annual sales in the US market currently.
- Zydus’s approval count climbs to 428 ANDAs filed.
- Strong financial growth: Net profit jumped 38% in Q2 FY26.
- Innovative company empowers healthier lives globally – 27,000 employees.
These new Verapamil tablets will be made at Zydus’s factory in Baddi, India. Experts say the market for this type of medicine is growing, with sales reaching $24.5 million each year in the United States. This is a big win for Zydus, as it’s their 428th approval for a generic drug.
Zydus Lifesciences is a big company focused on making and selling medicines. They’ve been working on this for a long time – since 2003! They make over 27,000 medicines worldwide and are trying to help people live healthier lives.
Recently, Zydus had a good quarter, with their profits increasing by 38% and their sales rising by 18%. The stock price of the company also went up a little bit, showing investors are confident in its future.
“This approval demonstrates Zydus’s commitment to providing affordable and effective healthcare solutions to patients worldwide.”
